ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1941

Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents
Abstract Number: 1298

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis
Abstract Number: 0911

Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis
Abstract Number: 1814

Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
Abstract Number: 1691

Pentagalloyl Glucose Inhibits MSU-Induced Inflammation via Transforming Growth Factor-β-Activated Kinase 1 (TAK1)
Abstract Number: 1705

Peptidoglycan Amplifies CD4+ T Cell Activation by MHCII+ Fibroblast-like Synoviocytes in an in Vitro Model of Lyme Arthritis
Abstract Number: 1682

Peptidyl Arginine Deiminase Expression and Macrophage Polarization Following Stimulation with Citrullinated and Malondialdehyde-acetaldehyde Modified Fibrinogen
Abstract Number: 1098

Perceived Barriers and Opportunities to Accessing Rheumatoid Arthritis Care on Navajo Nation: The Primary Care Providers’ Perspectives
Abstract Number: 0631

Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease
Abstract Number: 0455

Performance of 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Turkish Vasculitis Patients
Abstract Number: 0803

Performance of Adenosine Deaminase Activity in Sinovial Fluid for the Early Diagnosis of Tuberculous Arthritis: A Meta Analysis
Abstract Number: 1774

Performance of an Early Triage System for Identification of Patients with Inflammatory Rheumatic Diseases
Abstract Number: 1037

Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies
Abstract Number: 0392

Performance of Clinical, Laboratory and Imaging Features for the Diagnosis of Axial Spondyloarthritis – A Systematic Literature Review
Abstract Number: 0334

Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].